Today, biopsies and scans aren’t the only ways to detect cancer; tumors also shed DNA, RNA, and proteins that can be detected in the bloodstream. Freenome is developing multiomics tests that use machine learning to detect complex patterns in both tumor-derived and non-tumor-derived biomarkers, making it possible to diagnose cancers earlier, when they’re more treatable. The company began with a blood-based test for colorectal cancer and is preparing for large studies of tests for multiple cancers.
News & Insights
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules